These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31803734)

  • 1. Screening of Methylation Signature and Gene Functions Associated With the Subtypes of Isocitrate Dehydrogenase-Mutation Gliomas.
    Pan X; Zeng T; Yuan F; Zhang YH; Chen L; Zhu L; Wan S; Huang T; Cai YD
    Front Bioeng Biotechnol; 2019; 7():339. PubMed ID: 31803734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the Gene Expression Rules That Define the Subtypes in Glioma.
    Cai YD; Zhang S; Zhang YH; Pan X; Feng K; Chen L; Huang T; Kong X
    J Clin Med; 2018 Oct; 7(10):. PubMed ID: 30322114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
    Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
    Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
    Zhang X; Tian Q; Wang L; Liu Y; Li B; Liang Z; Gao P; Zheng K; Zhao B; Lu H
    J Magn Reson Imaging; 2018 Oct; 48(4):916-926. PubMed ID: 29394005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinguishing Glioblastoma Subtypes by Methylation Signatures.
    Zhang YH; Li Z; Zeng T; Pan X; Chen L; Liu D; Li H; Huang T; Cai YD
    Front Genet; 2020; 11():604336. PubMed ID: 33329750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
    Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
    Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array.
    Li J; Xue Y; Wenger A; Sun Y; Wang Z; Zhang C; Zhang Y; Fekete B; Rydenhag B; Jakola AS; Jiang T; Carén H; Fan X
    Clin Cancer Res; 2019 Dec; 25(23):7068-7077. PubMed ID: 31481507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGFBP2 expression predicts IDH-mutant glioma patient survival.
    Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
    Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raman Spectroscopy and Machine Learning for IDH Genotyping of Unprocessed Glioma Biopsies.
    Sciortino T; Secoli R; d'Amico E; Moccia S; Conti Nibali M; Gay L; Rossi M; Pecco N; Castellano A; De Momi E; Fernandes B; Riva M; Bello L
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Liu X; Li Y; Li S; Fan X; Sun Z; Yang Z; Wang K; Zhang Z; Jiang T; Liu Y; Wang L; Wang Y
    Aging (Albany NY); 2019 Jan; 11(2):673-696. PubMed ID: 30696801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.